Previously monoclonal antibody therapy directed at MUC-1 from normal tissues was ineffective but recent advancements in targeting tumor Muc1 has been promising in monoclonal antibody studies and CAR-T cell directed therapy (Danielczyk et al. 2006; Posey et al. 2016). The gene discussed is MUC1; the disease is neoplasm.